161Tb-PSMA-I&T is a terbium analogue of 177Lu-Vipivotide tetraxetan and the clinically developed alternative to 161Tb-PSMA-617. The advantage of using Terbium-161 is the possibility to develop analogues of the same atom in particular the alpha emitting terbium isotope 149Tb. Another advantage of 161Tb, compared to 177Lu, is linked to its additional emission of Auger/conversion electrons which could translate energy in higher efficacy.
A clinical trial (Phase 0/I) is under preparation at the Peter MacCallum Cancer Centre, Melbourne, Australia.
Radiation Type: beta electrons (β–)